ISSN |
1948-5204 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Pathology |
Manuscript Type |
Basic Study |
Article Title |
Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Xi Wang, Cheng-Sheng Zhang, Xu-Yuan Dong, Yuan Hu, Bao-Jun Duan, Jun Bai, Yin-Ying Wu, Lin Fan, Xin-Hua Liao, Ye Kang, Peng Zhang, Meng-Yang Li, Jiao Xu, Zhi-Jun Mao, Hui-Tong Liu, Xiao-Long Zhang, Li-Fei Tian and En-Xiao Li |
ORCID |
|
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Basic Research Project of Natural Science of Shaanxi Province |
2020JQ-943 |
Basic Research Project of Natural Science of Shaanxi Province |
2021JQ-916 |
Basic Research Project of Natural Science of Shaanxi Province |
2021JQ-914 |
Research Project of Chinese Society of Clinical Oncology-Sai Sheng Fund |
Y-2020Sciclone/qn-0181 |
Science and Technology Support Program of Shaanxi Provincial People's Hospital |
2021JY-26 |
Science and Technology Support Program of Shaanxi Provincial People's Hospital |
2021JY-38 |
Science and Technology Support Program of Shaanxi Provincial People's Hospital |
2021JY-50 |
Science and Technology Support Program of Shaanxi Provincial People's Hospital |
2021BJ-13 |
Research Fund Project of Shaanxi Provincial People’s Hospital |
2021YJY-18 |
China Postdoctoral Science Foundation |
2021M702607 |
|
Corresponding Author |
En-Xiao Li, PhD, Professor, Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 West Yanta Road, Xi'an 710061, Shaanxi Province, China. doclienxiao@sina.com |
Key Words |
Pancreatic ductal adenocarcinoma; Claudin 18.2, Immunohistochemistry; Therapeutic target; Diagnosis; Prognosis |
Core Tip |
Claudin 18.2 (CLDN18.2) shows a high rate of expression in pancreatic ductal adenocarcinoma (PDAC) but displays little expression in normal pancreatic tissue. CLDN18.2 expression significantly correlates with lymph node metastasis, distant metastasis, nerve invasion, stage, and survival of PDAC patients. Thus, CLDN18.2 may act as an ideal therapeutic target, and a considerable number of PDAC patients may be in eligible for a CLDN18.2-targeted therapeutic approach. |
Publish Date |
2022-07-13 01:27 |
Citation |
Wang X, Zhang CS, Dong XY, Hu Y, Duan BJ, Bai J, Wu YY, Fan L, Liao XH, Kang Y, Zhang P, Li MY, Xu J, Mao ZJ, Liu HT, Zhang XL, Tian LF, Li EX. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2022; 14(7): 1252-1264 |
URL |
https://www.wjgnet.com/1948-5204/full/v14/i7/1252.htm |
DOI |
https://dx.doi.org/10.4251/wjgo.v14.i7.1252 |